---> TTNP the next ENMD? Great News Coming, $4 5/8!
Titan Pharmaceuticals Inc.(Nasdaq:TTNP) said it has had positive preliminary results in three Phase I/II clinical trials of its therapeutic cancer vaccines.
Titan said results of two continuing clinical studies of TriAb showed consistent immune responses generated in patients with metastatic breast cancer, as well as in earlier-stage post-surgical breast cancer patients.
Based on these promising initial results, the company is planning efficacy studies in patients with breast cancer and ovarian cancer, it said.
The company also plans further expanded studies utilizing TriGem in patients with melanoma and small cell lung cancer, to determine the efficacy of TriGem in these patient groups.